Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
复制标题
DOI:
10.1136/bjophthalmol-2021-319530
复制
发表时间:
2022-10
期刊:
影响因子:
--
通讯作者:
Siesky B
中科院分区:
文献类型:
--
作者:
Stoner A;Harris A;Oddone F;Belamkar A;Verticchio Vercellin AC;Shin J;Januleviciene I;Siesky B
Carbonic anhydrase inhibitors (CAIs) have been used for many decades in the treatment of glaucoma. Systemic CAIs were an early treatment option to lower intraocular pressure by reducing aqueous humour production; however, frequent side effects including polyuria and paresthesia contributed to the eventual development of topical CAIs. As topical drug development evolved over time, prostaglandin analogues and beta-blockers have become the gold standard of glaucoma therapies. Although prescribed less often than other classes of topical glaucoma therapies, topical CAIs continue to be used in combination therapies with beta-blockers and alpha agonists. Topical CAIs have also been demonstrated to alter biomarkers of ocular haemodynamics, which have relevance in glaucoma. The purpose of this review is to review and summarise the current state of topical CAI prescribing trends, known efficacy and suggested mechanisms and potential influence on ocular haemodynamics for the future of glaucoma management.
登录
查看更多内容
影响因子:
13.7
作者:
Harris, A;Arend, O;Martin, B
通讯作者:
Martin, B
影响因子:
3.9
作者:
Fechtner, R. D.;Myers, J. S.;Hubatsch, D. A.;Budenz, D. L.;DuBiner, H. B.
通讯作者:
DuBiner, H. B.
影响因子:
7.3
作者:
Huang, Qinhua;Rui, Eugene Y.;Edwards, Martin P.
通讯作者:
Edwards, Martin P.
影响因子:
4.1
作者:
Fuchsjäger-Mahrl, G;Wally, B;Schmetterer, L
通讯作者:
Schmetterer, L
影响因子:
8.3
作者:
Dallinger, S;Bobr, B;Schmetterer, L
通讯作者:
Schmetterer, L